New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.
Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The pharmaceutical giant’s blockbuster weight-loss drug beat sales expectations in the third quarter, sending shares higher in early trade.
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Novo Nordisk Posts Mixed Results, Adding to Jitters About Weight-Loss Drugs
A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may have overestimated the market for its new weight-loss and diabetes medicines.
Novo Nordisk aware of 10 deaths related to weight-loss drug copies - report
Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs Wegovy and Ozempic, its CFO Karsten Munk Knudsen told a media
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said. The company is still "evaluating" the price of the drug,
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans ...
Viking Therapeutics' New Weight Loss Pill Shows Promising Results
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
BBC2d
Nurse’s death linked to approved weight-loss drug
but the emergence of new weight-loss jabs seemed to her to offer better chances of success. After researching Mounjaro ...
Yahoo5d
A new weight loss pill outperformed Novo Nordisk's version
Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill. The San Diego-based company’s stock ...
Clinical trial offers new hope for weight loss seekers
Amid growing concerns over counterfeit weight loss medications, a local clinical trial may offer a safer alternative for ...
Analysis-Americans Hungry for Weight-Loss Drugs Grapple With Supply and Insurance Hurdles
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
News Medical on MSN5d
Weight loss drug semaglutide may offer relief for knee arthritis pain
Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.